Mitchel L. Zoler, PhD
News
FDA advisers set high bar for new opioids
January 21, 2020
Two days of FDA discussion over three new opioids seeking U.S. approval highlighted the barriers these drugs now face.
News
New hypertension performance measures boost 130/80 mm Hg target
January 6, 2020
PHILADELPHIA – Hypertension performance and quality measures from the AHA and ACC provide a guide for implementing the 2017 hypertension guideline.
News
Genetic test stratified AFib patients with low CHA2DS2-VASc scores
December 9, 2019
A 32-locus genetic test classified AFib patients with low CHA2DS2-VASc scores into high– and low–stroke-risk subgroups.
News
New heart failure trial data presage guideline revisions
December 9, 2019
PHILADELPHIA – Recent trial findings for sacubitril/valsartan and dapagliflozin in heart failure patients provide a blueprint for guideline changes.
News
DAPA-HF: Dapagliflozin benefits regardless of age, HF severity
November 25, 2019
PHILADELPHIA – The SGLT2 inhibitor had similar efficacy in the elderly, and across the spectrum of baseline symptom status.
News
Previously healthy patients hospitalized for sepsis show increased mortality
November 5, 2019
WASHINGTON – U.S. patients hospitalized with community-acquired sepsis had higher mortality when they had no other comorbidities.
Video
Beta-blockers effective, safe for HFrEF with renal dysfunction
September 23, 2019
PARIS – Meta-analysis of more than 17,000 heart failure patients showed efficacy and safety of beta-blockers in moderate renal dysfunction.
News
FDA’s low-risk TAVR okay set to propel case volume
August 27, 2019
The FDA’s approval of TAVR for low-risk patients should boost both case numbers and U.S. TAVR sites.
News
DOACs surpass warfarin in low-weight AFib patients
June 5, 2019
SAN FRANCISCO – Data from 21,000 Korean AFib patients weighing 60 kg or less showed DOACs had better efficacy and safety than did warfarin.
News
AFib screening cuts hospitalizations and ED visits
May 11, 2019
NEW ORLEANS – People diagnosed with atrial fibrillation by screening had fewer hospitalizations and ED visits than those diagnosed by usual care.